alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 476–500 of 516 studies with an author at UCL Queen Square Institute of Neurology (GB) · free to read (page 20 of 21) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,651 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cerebrospinal fluid YKL‐40 relates to white matter hyperintensity progression in females but not males over a 6‐year period

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

= 0.71) longitudinally. YKL-40 associations with FW and FW-corrected fractional anisotropy were null. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of neurology 2024-12-12

Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient's symptoms. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques

✓ Peer-reviewed alzhub usefulness score 42 out of 100. The Journal of biological chemistry 2005-08-09

Familial Danish dementia is an early onset autosomal dominant neurodegenerative disorder linked to a genetic defect in the BRI2 gene and clinically characterized by dementia and ataxia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Stem cell reports 2017-03-09

Human stem cell models have the potential to provide platforms for phenotypic screens to identify candidate treatments and cellular pathways involved in the pathogenesis of neurodegenerative disorders. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

“Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain”

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Molecular psychiatry 2020-01-31

A population of >6 million people worldwide at high risk of Alzheimer’s disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of β-amyloid-(Aβ)-precursor-protein gene. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers

✓ Peer-reviewed alzhub usefulness score 42 out of 100. BMC neurology 2024-04-09

The authors sought to examine the impact of the K-variant of butyrylcholinesterase (BCHE-K) carrier status on age-at-diagnosis of Alzheimer disease (AD) in APOE4 carriers. 4 key findings →

Design: post-hoc analysis Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2020-01-02

We conclude that an inverse correlation between levels of inflammation in cortical areas and plasma NfL levels indicates that microglial activation may initially be protective to axons in AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

P1‐243: BIOMARKER‐GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER'S DISEASE USING UNSUPERVISED CLUSTERING METHODS

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2019-07-01

We found 5 distinct clusters of subjects (N=38, N=16, N=24, N=14, N=21) with a composition statistically independent from that obtained using available clinical diagnostic criteria (each cluster included all phenotypical groups). 3 key findings →

Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration

✓ Peer-reviewed alzhub usefulness score 41 out of 100. American Journal of Roentgenology 2026-09-16

Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Investigating the Utility of Explainable Artificial Intelligence for Neuroimaging‐Based Dementia Diagnosis and Prognosis

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Human Brain Mapping 2026-02-01

Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The experience of “at‐risk” status for familial frontotemporal dementia (fFTD) and its impact on reproductive decision‐making: A qualitative study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Genetic Counseling 2025-01-12

Familial frontotemporal dementia (fFTD) is an autosomal dominant heritable form of FTD, onsetting in mid-life, characterized by behavioral and personality changes. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations of plasma p‐tau231 with serial position recall performance in free‐of‐dementia individuals

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Neuropsychology 2025-09-23

Cognitive assessment and analysis of plasma biomarkers are lower-cost options for the early assessment of Alzheimer's disease (AD). 1 key finding →

Participants: 327 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Independent and interactive contributions of white matter hyperintensities and Alzheimer’s disease imaging and plasma biomarkers to cognitive decline in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s Research & Therapy 2026-03-30

Individual biomarkers significantly predict decline across multiple cognitive domains. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular therapy : the journal of the American Society of Gene Therapy 2025-12-24

Alzheimer's disease (AD) is characterized by a progressive cognitive decline involving a multifactorial pathophysiology, including epigenetic dysregulation. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identification of genetic modifiers influencing disease risk in autosomal dominant Alzheimer disease mutation carriers

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Finally, at the RHOJ locus, the rare allele was associated with increased tTau ( p ‐value=4.74×10 ‐05 ) and pTau181 ( p ‐value=4.07×10 ‐07 ), and decreased Aβ42/40 ratio ( p ‐value=4.32×10 ‐05 ). 2 key findings →

Participants: 91 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s Research & Therapy 2025-05-24

In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Regional Health - Western Pacific 2025-02-01

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Communications Medicine 2025-12-12

Accurate diagnosis of frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance remains challenging due to lack of clinical characterization, and standardized terminology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated